NVS – Novartis AG
Novartis AGNVS
$123.10Name : Novartis AG
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $243,133,579,264.00
EPSttm : 6.38
Novartis AG
$123.10
1.73%$2.09Float Short %
0.2
Margin Of Safety %
-6
Put/Call OI Ratio
1.15
EPS Next Q Diff
-0.11
EPS Last/This Y
2.87
EPS This/Next Y
0.32
Price
121.01
Target Price
122.68
Analyst Recom
3.04
Performance Q
7.5
Relative Volume
0.68
Beta
0.59
Ticker: NVS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | NVS | 116.67 | 1.50 | 0.09 | 68894 |
| 2025-06-03 | NVS | 115.97 | 1.50 | 1.92 | 68911 |
| 2025-06-04 | NVS | 116.96 | 1.50 | 0.38 | 69027 |
| 2025-06-05 | NVS | 117.8 | 1.50 | 0.35 | 69059 |
| 2025-06-06 | NVS | 118.02 | 1.50 | 3.65 | 69109 |
| 2025-06-09 | NVS | 118.05 | 1.50 | 0.28 | 69291 |
| 2025-06-10 | NVS | 118.64 | 1.51 | 1.34 | 68921 |
| 2025-06-11 | NVS | 118.02 | 1.52 | 0.09 | 69245 |
| 2025-06-12 | NVS | 120.75 | 1.51 | 0.25 | 69383 |
| 2025-06-13 | NVS | 119.5 | 1.50 | 1.55 | 69749 |
| 2025-06-16 | NVS | 118.14 | 1.51 | 0.87 | 69965 |
| 2025-06-17 | NVS | 116.42 | 1.51 | 0.58 | 70035 |
| 2025-06-18 | NVS | 115.99 | 1.51 | 0.36 | 70022 |
| 2025-06-20 | NVS | 115.74 | 1.51 | 0.09 | 70367 |
| 2025-06-23 | NVS | 117.58 | 1.19 | 0.06 | 51815 |
| 2025-06-24 | NVS | 118.85 | 1.15 | 0.52 | 52713 |
| 2025-06-25 | NVS | 117.99 | 1.15 | 1.11 | 52888 |
| 2025-06-26 | NVS | 120.33 | 1.15 | 0.56 | 53065 |
| 2025-06-27 | NVS | 120.06 | 1.11 | 2.46 | 55245 |
| 2025-06-30 | NVS | 120.98 | 1.15 | 4.50 | 56671 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | NVS | 116.69 | 18.9 | 3872.4 | 8.83 |
| 2025-06-03 | NVS | 115.94 | 18.9 | 3578.7 | 8.84 |
| 2025-06-04 | NVS | 116.97 | 18.9 | 3556.7 | 8.84 |
| 2025-06-05 | NVS | 117.79 | 18.9 | 3694.1 | 8.84 |
| 2025-06-06 | NVS | 118.01 | 18.9 | 3480.0 | 8.84 |
| 2025-06-09 | NVS | 118.02 | 18.9 | 3436.7 | 8.84 |
| 2025-06-10 | NVS | 118.59 | 18.9 | 3563.5 | 8.84 |
| 2025-06-11 | NVS | 118.00 | 18.9 | 3383.5 | 8.84 |
| 2025-06-12 | NVS | 120.77 | 18.9 | 3918.9 | 8.84 |
| 2025-06-13 | NVS | 119.35 | 18.9 | 3436.2 | 8.84 |
| 2025-06-16 | NVS | 118.11 | 18.9 | 3212.4 | 8.84 |
| 2025-06-17 | NVS | 116.39 | 18.9 | 3163.1 | 8.84 |
| 2025-06-18 | NVS | 115.96 | 18.9 | 3280.7 | 8.84 |
| 2025-06-20 | NVS | 115.77 | 18.9 | 3427.7 | 8.84 |
| 2025-06-23 | NVS | 117.59 | 18.9 | 3710.1 | 8.84 |
| 2025-06-24 | NVS | 118.87 | 18.9 | 3899.8 | 8.84 |
| 2025-06-25 | NVS | 118.00 | 18.9 | 3068.8 | 8.84 |
| 2025-06-26 | NVS | 120.33 | 18.9 | 3435.9 | 8.84 |
| 2025-06-27 | NVS | 120.01 | 18.9 | 3170.0 | 8.84 |
| 2025-06-30 | NVS | 121.01 | 18.9 | 3225.6 | 8.79 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | NVS | 0 | 0.93 | 0.18 |
| 2025-06-03 | NVS | 0 | 0.93 | 0.18 |
| 2025-06-04 | NVS | 0 | 0.93 | 0.18 |
| 2025-06-05 | NVS | 0 | 0.93 | 0.18 |
| 2025-06-06 | NVS | 0 | 0.93 | 0.18 |
| 2025-06-09 | NVS | 0 | 0.72 | 0.18 |
| 2025-06-10 | NVS | 0 | 0.72 | 0.18 |
| 2025-06-11 | NVS | 0 | 0.72 | 0.18 |
| 2025-06-12 | NVS | 0 | 0.72 | 0.18 |
| 2025-06-13 | NVS | 0 | 0.72 | 0.18 |
| 2025-06-16 | NVS | 0 | 0.71 | 0.18 |
| 2025-06-17 | NVS | 0 | 0.71 | 0.18 |
| 2025-06-18 | NVS | 0 | 0.71 | 0.18 |
| 2025-06-20 | NVS | 0 | 0.71 | 0.18 |
| 2025-06-23 | NVS | 0 | 1.00 | 0.18 |
| 2025-06-24 | NVS | 0 | 1.00 | 0.18 |
| 2025-06-25 | NVS | 0 | 1.00 | 0.18 |
| 2025-06-26 | NVS | 0 | 1.00 | 0.20 |
| 2025-06-27 | NVS | 0 | 1.00 | 0.20 |
| 2025-06-30 | NVS | 0 | 0.63 | 0.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.28
Avg. EPS Est. Current Quarter
2.34
Avg. EPS Est. Next Quarter
2.17
Insider Transactions
Institutional Transactions
0.63
Beta
0.59
Average Sales Estimate Current Quarter
14014
Average Sales Estimate Next Quarter
13402
Fair Value
114.31
Quality Score
97
Growth Score
75
Sentiment Score
97
Actual DrawDown %
-0.1
Max Drawdown 5-Year %
-20.4
Target Price
122.68
P/E
18.94
Forward P/E
13.57
PEG
2.84
P/S
4.44
P/B
6.18
P/Free Cash Flow
13.04
EPS
6.39
Average EPS Est. Cur. Y
8.79
EPS Next Y. (Est.)
9.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
24.86
Relative Volume
0.68
Return on Equity vs Sector %
9.7
Return on Equity vs Industry %
1.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.02
EBIT Estimation
3225.6
Novartis AGSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75883
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading